Publication
Imunoterapia anti-tumoral com células dendríticas
| Summary: | Dendritic cells (DCs) are professional antigen-presenting cells, which display an extraordinary capacity to induce and regulate T-cell responses. Because of their immunoregulatory capacities and because very small numbers of activated DCs are highly efficient in generating immune responses against antigens, DCs have been extensively used in clinical trials in order to elicit or amplify immune responses against cancer. While clinical trials provide evidence that dendritic cells vaccines are safe and elicit immunological responses in most patients, few complete tumor remissions have been reported. To improve the clinical efficacy, it is mandatory to design novel and improved strategies that can boost adaptive immunity to cancer helping to overcome regulatory T cells and allowing the breakdown of the immunosuppressive tumor microenvironment. The association of DCs vaccines with conventional chemo- and radiotherapy protocols could enhance DCs activation and antigen cross-presentation, selectively eliminating immunosuppressive cells, thus reverting the immunosuppression state caused by cancer, suggesting that relevant chemoimmunotherapy associa- tions could fully exploit DC capacity to trigger anticancer responses. |
|---|---|
| Main Authors: | Oliveira, T.G |
| Other Authors: | Borges, O.; Cruz, M.T. |
| Subject: | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| Year: | 2013 |
| Country: | Portugal |
| Document type: | article |
| Associated institution: | Ordem dos Farmacêuticos do Porto |
| Language: | Portuguese |
| Origin: | Acta Farmacêutica Portuguesa |
| _version_ | 1877792667448901632 |
|---|---|
| author | Oliveira, T.G |
| author2 | Borges, O. Cruz, M.T. |
| author2_role | author author |
| author_facet | Oliveira, T.G Borges, O. Cruz, M.T. |
| author_role | author |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Oliveira, T.G\"},{\"Person.name\":\"Borges, O.\"},{\"Person.name\":\"Cruz, M.T.\"}] |
| datacite.creators.creator.creatorName.fl_str_mv | Oliveira, T.G Borges, O. Cruz, M.T. |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| datacite.titles.title.fl_str_mv | Imunoterapia anti-tumoral com células dendríticas Imunoterapia anti-tumoral com células dendríticas |
| dc.creator.none.fl_str_mv | Oliveira, T.G Borges, O. Cruz, M.T. |
| dc.description.none.fl_str_mv | As células dendríticas (DCs) são células apresentadoras de antigénio dotadas de uma extraordinária capacidade de estimular e regular a resposta dos linfócitos T. Devido à sua capacidade imunomoduladora e ao reduzido número de DCs ativadas capazes de gerar uma eficiente resposta imunológica, as DCs têm sido muito utilizadas em ensaios clínicos com o intuito de obter ou amplificar uma resposta imune anti-tumoral. Apesar de estudos clínicos evidenciarem que as vacinas de DCs são seguras e induzem uma resposta imunológica na maioria dos doentes, o número de casos com remissões completas do tumor ainda é pequeno. Para aumentar a eficácia clínica é necessário melhorar e criar novas estratégias que incluam a amplificação da imunidade adaptativa anti-tumoral e o bloqueio da proliferação de linfócitos T reguladores e do micro-ambiente imunossupressor. A combinação de vacinas de DCs com os protocolos convencionais de quimio e radioterapia promovem a ativação de DCs, a apresentação cruzada de antigénios e a eliminação seletiva de células imunossupressoras, revertendo o estado de imunossupressão inerente ao tumor. Assim, esta associação de quimioimunoterapia poderá explorar positivamente a capacidade das DCs na obtenção de uma resposta imunológica mais eficaz. |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6 |
| dc.language.none.fl_str_mv | por |
| dc.publisher.none.fl_str_mv | Acta Farmacêutica Portuguesa |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.source.none.fl_str_mv | Acta Farmacêutica Portuguesa; v. 2 n. 2 (2013); 45-60 2182-3340 |
| dc.subject.none.fl_str_mv | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| dc.title.fl_str_mv | Imunoterapia anti-tumoral com células dendríticas Imunoterapia anti-tumoral com células dendríticas |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_6501 |
| description | Dendritic cells (DCs) are professional antigen-presenting cells, which display an extraordinary capacity to induce and regulate T-cell responses. Because of their immunoregulatory capacities and because very small numbers of activated DCs are highly efficient in generating immune responses against antigens, DCs have been extensively used in clinical trials in order to elicit or amplify immune responses against cancer. While clinical trials provide evidence that dendritic cells vaccines are safe and elicit immunological responses in most patients, few complete tumor remissions have been reported. To improve the clinical efficacy, it is mandatory to design novel and improved strategies that can boost adaptive immunity to cancer helping to overcome regulatory T cells and allowing the breakdown of the immunosuppressive tumor microenvironment. The association of DCs vaccines with conventional chemo- and radiotherapy protocols could enhance DCs activation and antigen cross-presentation, selectively eliminating immunosuppressive cells, thus reverting the immunosuppression state caused by cancer, suggesting that relevant chemoimmunotherapy associa- tions could fully exploit DC capacity to trigger anticancer responses. |
| dirty | 0 |
| eu_rights_str_mv | |
| format | article article |
| id | afp_2b35a4a13f8d6145f1248c197c37f7d9 |
| identifier.url.fl_str_mv | https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6 |
| inst_facet_str | urn:organizationAcronym:ofp{{{_:::_}}}Ordem dos Farmacêuticos do Porto |
| instacron_str | ofp |
| institution | Ordem dos Farmacêuticos do Porto |
| instname_str | Ordem dos Farmacêuticos do Porto |
| language | por |
| network_acronym_str | afp |
| network_name_str | Acta Farmacêutica Portuguesa |
| oai_identifier_str | oai:ojs.actafarmaceuticaportuguesa.com:article/6 |
| organization_str_mv | urn:organizationAcronym:ofp |
| person_str_mv | Oliveira, T.G Borges, O. Cruz, M.T. |
| publishDate | 2013 |
| publisher.none.fl_str_mv | Acta Farmacêutica Portuguesa |
| repo_facet_str | urn:repositoryAcronym:afp{{{_:::_}}}Acta Farmacêutica Portuguesa |
| reponame_str | Acta Farmacêutica Portuguesa |
| repository_id_str | urn:repositoryAcronym:afp |
| service_str_mv | urn:repositoryAcronym:afp |
| spelling | en-USImunoterapia anti-tumoral com células dendríticaspt-PTImunoterapia anti-tumoral com células dendríticasOliveira, T.GBorges, O.Cruz, M.T.Dendritic cellsCancerImmunotherapyVaccine.Células dendríticasCancroImunoterapiaVacinahttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6URLoai:ojs.actafarmaceuticaportuguesa.com:article/6OAIhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6URLhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6/106URLHasVersion2013-12-20T00:00:00Zhttp://purl.org/coar/access_right/c_abf2en-USDendritic cells (DCs) are professional antigen-presenting cells, which display an extraordinary capacity to induce and regulate T-cell responses. Because of their immunoregulatory capacities and because very small numbers of activated DCs are highly efficient in generating immune responses against antigens, DCs have been extensively used in clinical trials in order to elicit or amplify immune responses against cancer. While clinical trials provide evidence that dendritic cells vaccines are safe and elicit immunological responses in most patients, few complete tumor remissions have been reported. To improve the clinical efficacy, it is mandatory to design novel and improved strategies that can boost adaptive immunity to cancer helping to overcome regulatory T cells and allowing the breakdown of the immunosuppressive tumor microenvironment. The association of DCs vaccines with conventional chemo- and radiotherapy protocols could enhance DCs activation and antigen cross-presentation, selectively eliminating immunosuppressive cells, thus reverting the immunosuppression state caused by cancer, suggesting that relevant chemoimmunotherapy associa- tions could fully exploit DC capacity to trigger anticancer responses. pt-PTAs células dendríticas (DCs) são células apresentadoras de antigénio dotadas de uma extraordinária capacidade de estimular e regular a resposta dos linfócitos T. Devido à sua capacidade imunomoduladora e ao reduzido número de DCs ativadas capazes de gerar uma eficiente resposta imunológica, as DCs têm sido muito utilizadas em ensaios clínicos com o intuito de obter ou amplificar uma resposta imune anti-tumoral. Apesar de estudos clínicos evidenciarem que as vacinas de DCs são seguras e induzem uma resposta imunológica na maioria dos doentes, o número de casos com remissões completas do tumor ainda é pequeno. Para aumentar a eficácia clínica é necessário melhorar e criar novas estratégias que incluam a amplificação da imunidade adaptativa anti-tumoral e o bloqueio da proliferação de linfócitos T reguladores e do micro-ambiente imunossupressor. A combinação de vacinas de DCs com os protocolos convencionais de quimio e radioterapia promovem a ativação de DCs, a apresentação cruzada de antigénios e a eliminação seletiva de células imunossupressoras, revertendo o estado de imunossupressão inerente ao tumor. Assim, esta associação de quimioimunoterapia poderá explorar positivamente a capacidade das DCs na obtenção de uma resposta imunológica mais eficaz. Acta Farmacêutica Portuguesaapplication/pdfpt-PTActa Farmacêutica Portuguesa; v. 2 n. 2 (2013); 45-602182-3340porjournal articlehttp://purl.org/coar/resource_type/c_6501literatureVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85journal articlehttp://purl.org/coar/resource_type/c_6501literature |
| spellingShingle | Imunoterapia anti-tumoral com células dendríticas Oliveira, T.G Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| status | SINGLETON |
| status_str | VoR |
| subject.fl_str_mv | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| title | Imunoterapia anti-tumoral com células dendríticas |
| title_full | Imunoterapia anti-tumoral com células dendríticas |
| title_fullStr | Imunoterapia anti-tumoral com células dendríticas |
| title_full_unstemmed | Imunoterapia anti-tumoral com células dendríticas |
| title_short | Imunoterapia anti-tumoral com células dendríticas |
| title_sort | Imunoterapia anti-tumoral com células dendríticas |
| topic | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| topic_facet | Dendritic cells Cancer Immunotherapy Vaccine. Células dendríticas Cancro Imunoterapia Vacina |
| url | https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/6 |
| visible | 1 |
Funded activities
No funded projects found.